GSK 1322888
Alternative Names: 1322888; GSK1322888Latest Information Update: 18 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Gastrokinetics; Small molecules
- Mechanism of Action Motilin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastroparesis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Gastroparesis(In volunteers) in Australia (PO, Capsule)
- 24 Feb 2011 Phase-I clinical trials in Gastroparesis in Australia (PO)